Have Insiders Sold Cutia Therapeutics Shares Recently?
We note that the Cutia Therapeutics (HKG:2487) Founder, Lele Zhang, recently sold HK$658k worth of stock for HK$1.01 per share. On the bright side, that's just a small sale and only reduced their holding by 3.7%.
The Last 12 Months Of Insider Transactions At Cutia Therapeutics
Notably, that recent sale by Lele Zhang is the biggest insider sale of Cutia Therapeutics shares that we've seen in the last year. So it's clear an insider wanted to take some cash off the table, even slightly below the current price of HK$1.02. We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. However, while insider selling is sometimes discouraging, it's only a weak signal. We note that the biggest single sale was only 3.7% of Lele Zhang's holding.
Lele Zhang divested 909.40k shares over the last 12 months at an average price of CN¥1.03. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Check out our latest analysis for Cutia Therapeutics
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
Does Cutia Therapeutics Boast High Insider Ownership?
For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Our data indicates that Cutia Therapeutics insiders own about HK$22m worth of shares (which is 6.0% of the company). We do generally prefer see higher levels of insider ownership.
So What Does This Data Suggest About Cutia Therapeutics Insiders?
An insider sold stock recently, but they haven't been buying. And even if we look at the last year, we didn't see any purchases. While insiders do own shares, they don't own a heap, and they have been selling. We'd practice some caution before buying! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. While conducting our analysis, we found that Cutia Therapeutics has 3 warning signs and it would be unwise to ignore them.
But note: Cutia Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.